Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis
ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50-75
SponsorBeylikduzu State Hospital
About this trial
The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Postmenopausal women with DXA measurements performed within the last 6 months.
Aged 50-75 years
Disqualifiers
Refusal to participate in the study.
History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss.
Presence of psychiatric disorders.
Cognitive impairments.
Trial population
Postmenopausal women
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
No intervention
Diagnostic testNo intervention
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: Postmenopausal osteoporosis1 intervention
Group B: Postmenopausal non-osteoporotic women1 intervention
Trial outcomes
Primary outcomes
1
Presence of Stress Urinary Incontinence:
Stress urinary incontinence (SUI) is the involuntary leakage of urine during physical activities that increase abdominal pressure, such as coughing, sneezing, or lifting. In this study, the presence of SUI will be determined through a questionnaire that asks participants about symptoms and frequency of urine leakage during such activities.
Time frame
0 day2
Incontinence Quality of Life Scale (I-QOL):
The I-QOL is a validated questionnaire that measures the impact of urinary incontinence on a patient's quality of life. It assesses how incontinence affects daily activities, social interactions, and emotional well-being. Higher scores indicate better quality of life, while lower scores suggest that incontinence has a more significant negative impact on the patient's day-to-day functioning.
Time frame
0 day3
Skeletal Muscle Mass:
Measured by bioelectrical impedance analysis (BIA), this assesses the amount of muscle tissue in the body. Low skeletal muscle mass indicates sarcopenia.
Time frame
0 day4
Handgrip Strength
This is a simple test to measure muscle strength. Reduced handgrip strength is a sign of sarcopenia.
Time frame
0 daySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov